CorTec Achieves Major Neurotech Milestone with First Human Implantation of Brain-Computer Interface Developed in Germany

CorTec GmbH has announced the successful first human implantation of its Brain Interchange™ system, a closed-loop brain-computer interface (BCI) developed entirely in Germany. 

This marks a significant step in bringing advanced neurotechnology from the laboratory into clinical use.

The implantation procedure took place in late July at Harborview Medical Center in Seattle, USA, as part of a clinical trial approved by the US Food and Drug Administration (FDA) under an Investigational Device Exemption (IDE). 

The study is focused on assessing the initial safety of the BCI and exploring its ability to support motor recovery in stroke patients. 

Specifically, it aims to determine whether targeted electrical stimulation of the brain can improve upper-limb movement during rehabilitation.

CorTec’s Brain Interchange™ system offers real-time, personalised stimulation by continuously recording brain activity and delivering precise electrical signals. 

The goal is to support neuroplasticity—the brain's natural capacity to adapt and reorganise itself—which may help patients regain lost function more effectively.

The implanted system is fully wireless, representing a shift away from traditional designs that rely on physical connections. 

This makes it more suitable for long-term use and broadens its potential applications for various neurological conditions.